DDInter1744 DDInter927
Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations.[A1025,L7799,L7802] Tamoxifen is used alone or as an adjuvant in these treatments.[L7799,L7802] Tamoxifen may no longer be the preferred treatment for these types of cancers as patients generally have better survival, side effect profiles, and compliance with [anastrozole]. Tamoxifen was granted FDA approval on 30 December 1977.
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent . Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with high mortality rates and low therapeutic response from standard chemotherapies in relasping conditions. In a randomized trial, inotuzumab ozogamicin displayed higher percentages of patients undergoing longer periods of complete remission with no evidence of disease in comparison to patients receiving alternative chemotherapy .
Tamoxifen {u} (Compound) resembles {v} (Compound) Methadyl Acetate
Tamoxifen {u} may lead to a major life threatening interaction when taken with {v} Dextropropoxyphene
Tamoxifen {u} (Compound) resembles {v} (Compound) Naftifine
Tamoxifen {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Loperamide
Tamoxifen {u} may lead to a major life threatening interaction when taken with {v} Diphenhydramine
Tamoxifen {u} (Compound) treats {v} (Disease) breast cancer
Tamoxifen {u} (Compound) binds {v} (Gene) CYP2E1
Tamoxifen {u} (Compound) upregulates {v} (Gene) SC5D
Tamoxifen {u} (Compound) downregulates {v} (Gene) CCNB2
Tamoxifen {u} (Compound) causes {v} (Side Effect) Thirst
Tamoxifen (Compound) resembles Methadyl Acetate (Compound)
Tamoxifen may lead to a major life threatening interaction when taken with Dextropropoxyphene
Tamoxifen (Compound) resembles Naftifine (Compound)
Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Loperamide
Tamoxifen may lead to a major life threatening interaction when taken with Diphenhydramine
Tamoxifen (Compound) treats breast cancer (Disease)
Tamoxifen (Compound) binds CYP2E1 (Gene)
Tamoxifen (Compound) upregulates SC5D (Gene)
Tamoxifen (Compound) downregulates CCNB2 (Gene)
Tamoxifen (Compound) causes Thirst (Side Effect)